USADA announced today that U.S. cycling athlete, Andrew Tilin, of Oakland, California, has accepted a two-year period of ineligibility for an anti-doping rule violation based on his admitted use of the prohibited Anabolic Agents, synthetic testosterone and dehydroepiandrosterone (“DHEA”).
Synthetic testosterone and DHEA are prohibited substances in the class of Anabolic Agents under the USADA Protocol for Olympic and Paralympic Movement Testing and the International Cycling Union (“UCI”) anti-doping rules, both of which have adopted the World Anti-Doping Code (“Code”) and the World Anti-Doping Agency Prohibited List.
Tilin’s two-year period of ineligibility began on March 30, 2011, the day he accepted the sanction. Additionally, Tilin is disqualified from all competitive results achieved on and subsequent to January 1, 2008, which, by his admission and acceptance of sanction, is the date he first committed an anti-doping rule violation using these substances. The sanction includes the forfeiture of any medals, points and prizes.
In an effort to aid athletes, as well as all support team members such as parents and coaches, in understanding the rules applicable to them, USADA provides comprehensive instruction on its website on the testing process and prohibited substances, how to obtain permission to use a necessary medication, and the risks and dangers of taking supplements as well as performance-enhancing and recreational drugs. In addition, the agency manages a drug reference hotline, Drug Reference Online (www.GlobalDRO.com), conducts educational sessions with National Governing Bodies and their athletes, and proactively distributes a multitude of educational materials, such as the Prohibited List, easy-reference wallet cards, periodic newsletters, and protocol and policy reference documentation.
USADA is responsible for the testing and results management process for athletes in the U.S. Olympic and Paralympic Movement, and is equally dedicated to preserving the integrity of sport through research initiatives and educational programs.
For more information or media inquiries, click here.